PainReform Ltd. (NASDAQ:PRFX) Sees Significant Growth in Short Interest

PainReform Ltd. (NASDAQ:PRFX) was the recipient of a significant increase in short interest during the month of June. As of June 30th, there was short interest totaling 127,699 shares, an increase of 122.3% from the June 15th total of 57,440 shares. Based on an average daily volume of 2,063,956 shares, the short-interest ratio is presently 0.1 days. Currently, 22.4% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of PainReform in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

PainReform Stock Down 0.8%

NASDAQ:PRFX traded down $0.01 on Wednesday, reaching $1.22. The company’s stock had a trading volume of 184,717 shares, compared to its average volume of 1,655,200. PainReform has a 12-month low of $1.18 and a 12-month high of $17.95. The firm has a market cap of $1.06 million, a price-to-earnings ratio of -0.00 and a beta of 1.05. The stock has a 50 day moving average price of $1.60 and a 200 day moving average price of $2.53.

PainReform (NASDAQ:PRFX) last announced its quarterly earnings results on Thursday, March 26th. The company reported ($1.01) EPS for the quarter.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.